- Home
- VIVS vs GLTO Comparison
VIVS vs GLTO Comparison
Compare VIVS & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIVS
- GLTO
- Stock Information
- Founded
- VIVS 2007
- GLTO 2011
- Country
- VIVS United States
- GLTO Denmark
- Employees
- VIVS N/A
- GLTO N/A
- Industry
- VIVS Biotechnology: Biological Products (No Diagnostic Substances)
- GLTO Biotechnology: Pharmaceutical Preparations
- Sector
- VIVS Health Care
- GLTO Health Care
- Exchange
- VIVS Nasdaq
- GLTO Nasdaq
- Market Cap
- VIVS 4.7M
- GLTO 4.5M
- IPO Year
- VIVS N/A
- GLTO 2020
- Fundamental
- Price
- VIVS $3.19
- GLTO $18.03
- Analyst Decision
- VIVS
- GLTO Buy
- Analyst Count
- VIVS 0
- GLTO 1
- Target Price
- VIVS N/A
- GLTO $10.00
- AVG Volume (30 Days)
- VIVS 166.7K
- GLTO 6.9M
- Earning Date
- VIVS 11-07-2025
- GLTO 10-31-2025
- Dividend Yield
- VIVS N/A
- GLTO N/A
- EPS Growth
- VIVS N/A
- GLTO N/A
- EPS
- VIVS N/A
- GLTO N/A
- Revenue
- VIVS $142,000.00
- GLTO N/A
- Revenue This Year
- VIVS $42.38
- GLTO N/A
- Revenue Next Year
- VIVS $15.42
- GLTO N/A
- P/E Ratio
- VIVS N/A
- GLTO N/A
- Revenue Growth
- VIVS 94.52
- GLTO N/A
- 52 Week Low
- VIVS $1.41
- GLTO $2.01
- 52 Week High
- VIVS $21.96
- GLTO $31.70
- Technical
- Relative Strength Index (RSI)
- VIVS 51.15
- GLTO 93.65
- Support Level
- VIVS $2.90
- GLTO $3.64
- Resistance Level
- VIVS $3.48
- GLTO $4.13
- Average True Range (ATR)
- VIVS 0.34
- GLTO 1.51
- MACD
- VIVS -0.09
- GLTO 1.07
- Stochastic Oscillator
- VIVS 20.86
- GLTO 60.67
About VIVS VivoSim Labs Inc. Common Stock
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.